Development of non-small cell lung cancer tissue microar

利用我们的综合肺组织芯片，包括300例NSCLC病例和183例神经内分泌肿瘤，我们从事了肺癌诊断和预后的候选蛋白标志物的系统评价。在最近的一项研究中，我们发现核心染色体重塑因子之一BRM是NSCLC的预后因子。最近，我们与Phil Denis博士的小组合作，证明磷酸化激活AKT对肺癌具有预后价值。此外，我们与Curt Harris博士小组的工作也有助于确定羧肽酶E和γ-谷氨酰水解酶作为肺神经内分泌肿瘤的生物标志物。利用这一独特的资源，我们已经开发了一个全面的肺癌蛋白质表达谱，我们正在完成一个可搜索的数据库，以便通过互联网随时访问我们的结果。我们预计，这种独特的资源将导致许多富有成效的发现与研究人员内外的NCI。

Utilizing our comprehensive lung tissue microarray that included 300 NSCLC cases and 183 neuroendocrine tumors, we have engaged in a systematical evaluation of candidate protein markers for lung cancer diagnosis and prognosis. In a recent study, we showed that one of the core chromosome remodeling factors, BRM is a prognostic factor in NSCLC. Recently, we have collaborated with Dr. Phil Denis's group to show that AKT activation by phosporylation has prognostic value in lung cancers. In addition, our work with Dr. Curt Harris' group also helped identify that carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors. Using this unique resource, we have developed a comprehensive protein expression profile for lung cancer and a we are completing a searchable database to allow our results be readily accessed via the internet. We anticipate that this unique resource will lead to many fruitful discoveries with researchers both inside and outside of NCI.